Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 19NIH 6INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 1905Breast Neoplasms 1425Carcinoma, Non-Small-Cell Lung 1178Prostatic Neoplasms 740Colorectal Neoplasms 686Neoplasm Metastasis 623Multiple Myeloma 548Melanoma 529Ovarian Neoplasms 456Lung Neoplasms 447Lymphoma, Non-Hodgkin 385Lymphoma 374Recurrence 373Leukemia, Myeloid, Acute 370Pancreatic Neoplasms 358Carcinoma, Renal Cell 339Carcinoma, Hepatocellular 286Stomach Neoplasms 281Leukemia, Lymphocytic, Chronic, B-Cell 268Lymphoma, Follicular 254Head and Neck Neoplasms 246Glioblastoma 220Leukemia 215Small Cell Lung Carcinoma 183Lymphoma, Large B-Cell, Diffuse 183Squamous Cell Carcinoma of Head and Neck 181Urinary Bladder Neoplasms 175Carcinoma 175Uterine Cervical Neoplasms 174Advanced Solid Tumors 161

Interventions

Everolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Lymphangioleiomyomatosis × Clear all
NCT03525834 2021-09-09

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Novartis

Phase 4 Completed
40 enrolled 10 charts

Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma

NCT01059318 2020-11-19

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Novartis

Phase 2 Completed
24 enrolled 13 charts

Lymphangioleiomyomatosis

NCT00790400 2017-02-17

EXIST-2

Novartis

Phase 3 Completed
118 enrolled 15 charts
CNS

Tuberous Sclerosis 2, Astrocytoma, Hereditary Sensory and Autonomic Neuropathies, Seizures, Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡